Germline loss of PKM 2 promotes metabolic distress and hepatocellular carcinoma

[1]  Darjus F. Tschaharganeh,et al.  p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer , 2016, Cell.

[2]  S. Thorgeirsson,et al.  Functional and genetic deconstruction of the cellular origin in liver cancer , 2015, Nature Reviews Cancer.

[3]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[4]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[5]  P. Angus,et al.  Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. , 2015, World journal of gastroenterology.

[6]  I. Ng,et al.  Switching of Pyruvate Kinase Isoform L to M2 Promotes Metabolic Reprogramming in Hepatocarcinogenesis , 2014, PloS one.

[7]  William J. Israelsen,et al.  Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. , 2014, Molecular cell.

[8]  William J. Israelsen,et al.  Cell-State-Specific Metabolic Dependency in Hematopoiesis and Leukemogenesis , 2014, Cell.

[9]  N. Hay,et al.  The pentose phosphate pathway and cancer. , 2014, Trends in biochemical sciences.

[10]  Jaspinder Kaur.  A Comprehensive Review on Metabolic Syndrome , 2014, Cardiology research and practice.

[11]  Yun Jiang,et al.  Interleukin 18 accelerates the hepatic cell proliferation in rat liver regeneration after partial hepatectomy. , 2014, Gene.

[12]  Zachary W. Dwyer,et al.  SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. , 2014, Molecular cell.

[13]  Jie Li,et al.  PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells , 2013, Cell.

[14]  G. Hammoud,et al.  Primary hepatocellular carcinoma and metabolic syndrome: An update. , 2013, World journal of gastrointestinal oncology.

[15]  Ning Leng,et al.  EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments , 2013, Bioinform..

[16]  K. Aldape,et al.  ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect , 2012, Nature Cell Biology.

[17]  Eyal Gottlieb,et al.  Serine is a natural ligand and allosteric activator of pyruvate kinase M2 , 2012, Nature.

[18]  Christian M. Metallo,et al.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis , 2012, Nature chemical biology.

[19]  K. Aldape,et al.  PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis , 2012, Cell.

[20]  E. Brunt,et al.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. , 2012, Journal of hepatology.

[21]  Xueliang Gao,et al.  Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. , 2012, Molecular cell.

[22]  B. Knebel,et al.  Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass , 2012, PloS one.

[23]  Z. Bhujwalla,et al.  Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.

[24]  K. Aldape,et al.  Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation , 2011, Nature.

[25]  J. Gustafsson,et al.  Estrogen receptors and the metabolic network. , 2011, Cell metabolism.

[26]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[27]  S. Mazurek.  Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. , 2011, The international journal of biochemistry & cell biology.

[28]  Zhengyu Zha,et al.  Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. , 2011, Molecular cell.

[29]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[30]  Jason W. Locasale,et al.  Evidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cells , 2010, Science.

[31]  M. Assanah,et al.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer , 2010, Nature.

[32]  A. Krainer,et al.  The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism , 2010, Proceedings of the National Academy of Sciences.

[33]  X. Pi-Sunyer.  The Medical Risks of Obesity , 2002, Obesity surgery.

[34]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[35]  C. Thompson,et al.  The molecular determinants of de novo nucleotide biosynthesis in cancer cells. , 2009, Current opinion in genetics & development.

[36]  H. Christofk,et al.  Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.

[37]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[38]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[39]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[40]  Ronald A. DePinho,et al.  Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.

[41]  C. Boschek,et al.  Pyruvate kinase type M2 and its role in tumor growth and spreading. , 2005, Seminars in cancer biology.

[42]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[43]  Kohjiro Ueki,et al.  Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  T. Mak,et al.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. , 2004, The Journal of clinical investigation.

[45]  H. El‐Serag,et al.  Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. , 2004, Gastroenterology.

[46]  F. Alt,et al.  Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  T. Tanaka,et al.  The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. , 1987, The Journal of biological chemistry.

[48]  K. Aldape,et al.  EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis. , 2018, Molecular cell.

[49]  D. Giugliano,et al.  Metabolic Syndrome and Risk of Cancer , 2012, Diabetes Care.

[50]  Dan Y. Gui,et al.  Lack of evidence for PKM 2 protein kinase activity , 2015 .

[51]  Anderson.  Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis , 2012 .

[52]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[53]  Martin Renqiang Min,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[54]  P. Steinberg,et al.  Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. , 1998, Carcinogenesis.